FibroBiologics is focused on leveraging fibroblast technology for regenerative medicine, emphasizing the unique properties of fibroblasts as a viable alternative to stem cells. Fibroblasts are the most abundant cell type in the human body and play a crucial role in tissue regeneration, immune modulation, and wound healing. They are easier to source, culture, and differentiate compared to stem cells, making them a cost-effective option for various therapeutic applications. The company has developed a robust pipeline of products targeting chronic diseases, including multiple sclerosis, degenerative disc disease, and thymic involution, showcasing the potential of fibroblast-based therapies to improve patient outcomes.

The company's product pipeline includes several innovative therapies, such as CYWC628 for wound healing, CYMS101 for multiple sclerosis, and CybroCell™ for degenerative disc disease, all of which aim to harness the regenerative capabilities of fibroblasts. FibroBiologics has conducted pre-clinical studies and limited clinical trials that demonstrate the safety and efficacy of these therapies, particularly in autoimmune diseases and age-related organ decline. With over 150 patents, the company is positioned as a pioneer in the field, aiming to make fibroblast cell-based therapies more accessible and effective for patients suffering from chronic conditions.

United States

FibroBiologics is the world leader in cell therapy using fibroblasts to regenerate tissue and cure chronic diseases. Currently, FibroBiologics holds 150+ U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, and Cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

FibroBiologics

Company Details